Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
 - EconoTimes)
SOUTH SAN FRANCISCO, Calif., May 09, 2017 -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that clinical results from the Phase 2 study of cerdulatinib in patients with relapsed/refractory b-cell malignancies will be shared in an oral presentation at the International Conference on Malignant Lymphoma (ICML), which is taking place from June 14-17 in Lugano, Switzerland.
Cerdulatinib is an investigational oral, dual SYK/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancers. Cerdulatinib inhibits two key signaling pathways that promote cancer cell growth in certain hematologic malignancies.
Details regarding the oral presentation follow.
Oral Presentation Details:
- Abstract Title: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study in Patients with Relapsed/Refractory B-Cell Malignancies
- Presenting Author: P.A. Hamlin, Memorial Sloan Kettering Cancer Center
- Presentation Date and Time: June 15, 2017 at 4:40 p.m. CEST
- Location: Room A, Cinema Corso and Aula Magna (Lugano University)
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Ana Kapor Portola Pharmaceuticals [email protected] Media Contact: Julie Normart Pure Communications [email protected] 415.946.1087
